← All trials
NCT04784767
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 5, 2021
- Primary completion
- Oct 30, 2022
- Completion date
- Oct 30, 2023
- First posted
- Mar 5, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 29
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- United States ArmyLead sponsor
- United States ArmyOverall official - principal investigator
- United States ArmyCollaborator
- Henry M. Jackson Foundation for the Advancement of Military MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.